Pep IQ
← Pep IQ
Substantial within the Khavinson research framework. Multiple mouse and rat studies (Anisimov, Khavinson and colleagues) reported 12–24% extension in median lifespan. A 2002 International Journal of Cancer paper reported reduced mammary tumour incidence and extended lifespan in HER-2/neu transgenic mice — counterintuitive for a telomerase activator and warranting independent replication. Cell-line work showed Epitalon (Ala-Glu-Asp-Gly tetrapeptide) activates hTERT expression and increases telomerase activity in human fetal fibroblasts beyond the Hayflick limit. A 2024 PMC paper (independent of Khavinson group) confirmed hTERT upregulation in 21NT and BT474 human cell lines.
Community protocols converge on 5–10 mg SubQ daily for 10–20 consecutive days, repeated 2–3 times per year — short intensive cycles, not continuous daily use. This is the Khavinson clinical protocol. Some users run intranasal. The cycling pattern is intentional: telomerase activation and biological effects persist beyond the injection period, so chronic dosing is unnecessary and not what the research base supports.
Human evidence is limited to small Russian studies and case reports. Khavinson group reports significantly increased telomere lengths in blood cells of patients aged 60–80. A trial in retinitis pigmentosa patients reported positive clinical effect in 90% of treated cases. A pulmonary tuberculosis study reported chromosomal protective effects. No large randomised controlled Western trials exist. A 2024 case report (Restorative Medicine Journal) using Epitalon as part of a broader anti-ageing protocol reported 0.14 kb telomere increase and 8-year biological age reduction — but this was a single case with multiple interventions.
Not approved as a medicine in any Western country. Sold as a research-peptide compound. Long Russian clinical use without major safety signals reported. The theoretical telomerase-cancer concern is genuine — cancer cells use telomerase for immortality — but the Anisimov 2002 mammary cancer mouse study showed reduced tumour incidence rather than increased, complicating the simple concern.
Epitalon has a coherent telomerase-pineal mechanism, real cell-line evidence (now independently replicated by a 2025 UK university group), and decades of Russian clinical use behind a defined short-course protocol (5–10 mg × 10–20 days, 2–3× per year). Large Western RCTs do not exist. The published evidence base is the Khavinson framework. Community use follows the same defined-cycle pattern rather than continuous administration.
Epitalon's story begins in the 1970s in St. Petersburg, Russia, where Professor Vladimir Khavinson and his colleagues at the Institute of Bioregulation and Gerontology were extracting peptide complexes from animal organs to study their regulatory effects on ageing. From bovine pineal gland tissue they isolated a polypeptide complex called Epithalamin, which showed remarkable effects on lifespan and tumour suppression in animal studies.
The active component of Epithalamin was eventually identified and synthesised as a simple four amino acid sequence: Ala-Glu-Asp-Gly (AEDG) — named Epitalon. The peptide is naturally produced by the pineal gland in tiny amounts, and its production appears to decline with age alongside melatonin — the gland's most famous product.
The research base for Epitalon, like several other longevity peptides in this book, is heavily concentrated in Russian institutions. Khavinson's group has published extensively over more than 50 years, and for a long time this was the only literature available. More recently, independent groups — including a 2025 study from Brunel University in the UK — have begun to validate some of the core findings, particularly around telomerase activation. This is a meaningful development: independent replication is what separates interesting findings from credible ones.
The single-source caveat: Most Epitalon research originates from Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology. While Epitalon has more independent replication than some other peptides in this space, the volume of research from a single group — over decades — means the same cautions apply as with BPC-157: interpretation should account for potential publication bias and the absence of adversarial scrutiny.
To understand Epitalon's core claim, you need to understand telomeres. Telomeres are protective caps at the ends of chromosomes — often compared to the plastic tips on shoelaces. Every time a cell divides, telomeres shorten slightly. When they become critically short, the cell can no longer divide — it enters senescence or dies. This limit on cell divisions is called the Hayflick limit.
Telomerase is the enzyme that rebuilds telomeres, maintaining their length and extending the replicative lifespan of cells. In most adult somatic cells, telomerase activity is very low — cells age and eventually stop dividing. The central claim for Epitalon is that it can activate telomerase in human somatic cells, potentially extending telomere length and pushing cells beyond the Hayflick limit.
The cancer question is the unavoidable counterpoint to telomerase activation. Telomerase is also active in approximately 85-90% of cancer cells — the enzyme that allows tumours to divide indefinitely is the same enzyme Epitalon is trying to activate. Research from 2025 offers a nuanced complication: in cancer cells specifically, Epitalon appears to work through a different pathway (ALT — alternative lengthening of telomeres) rather than direct telomerase upregulation, and may actually have anti-tumour properties in some cancer cell lines. This is an active area of research and the full implications are not yet clear.